Valuation: Processa Pharmaceuticals, Inc.

Market Cap 5.78M 4.99M 4.69M 4.27M 8.02M 553M 8.14M 55.05M 21.58M 277M 21.68M 21.21M 922M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value 238K 206K 194K 176K 331K 22.84M 336K 2.27M 891K 11.42M 895K 876K 38.05M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Processa Pharmaceuticals, Inc.

1 day+1.43%
1 week-14.84%
Current month+1.40%
1 month-1.80%
3 months-16.48%
6 months-4.39%
Current year-24.31%
1 week 2.04
Extreme 2.04
2.59
1 month 1.8
Extreme 1.8
3.11
Current year 1.67
Extreme 1.6701
3.8
1 year 1.67
Extreme 1.6701
14.24
3 years 1.67
Extreme 1.6701
450
5 years 1.67
Extreme 1.6701
4,495.35
10 years 1.67
Extreme 1.6701
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 08/08/2023
Investor Relations Contact 60 29/03/2011
Chief Administrative Officer 61 04/10/2017
Director TitleAgeSince
Chairman 73 29/03/2011
Chairman 60 16/08/2022
Director/Board Member 56 13/02/2020
Date Insider Type Main position Quantity % Market Cap.
8/8/26 A Fiscal year

Chief Executive Officer

3,200 0.1156%
7/26/26 A Other

Chief Financial Officer

11,883 0.4293%
7/26/26 A Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
+3.81%-14.84%-57.77%-98.76% 5.78M
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.94%+15.37%+57.07%+92.50% 62.99B
+0.30%-3.08%+0.79%+482.77% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+19.65%+19.09%-0.86%-6.03% 23.3B
+2.28%+5.65%+42.00%-13.75% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.31%+8.17%+45.24%+155.01% 13.16B
Average +2.01%+0.45%+47.12%+170.06% 28.05B
Weighted average by Cap. +1.31%+4.39%+57.70%+164.62%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.23M -9.63M -8.75M -16.46M -1.14B -16.7M -113M -44.27M -568M -44.49M -43.53M -1.89B -13.56M -11.72M -11.02M -10.02M -18.84M -1.3B -19.12M -129M -50.67M -650M -50.93M -49.82M -2.17B
Net Debt -1.12M -965K -908K -826K -1.55M -107M -1.58M -10.66M -4.18M -53.57M -4.2M -4.11M -178M -5.54M -4.78M -4.5M -4.09M -7.69M -531M -7.8M -52.78M -20.68M -265M -20.79M -20.34M -884M
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
19/08/26 $2.180 +3.81% 8,845
18/08/26 $2.100 -1.41% 51,877
17/08/26 $2.130 -12.35% 61,305
14/08/26 $2.430 -2.80% 50,194
13/08/26 $2.500 -2.34% 38,451

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PCSA Stock